LBRX (STOCKS)
LB Pharmaceuticals Inc Common Stock
$44.270000
-1.110000 (-2.45%)
Prev close: $45.380000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Heather D. Turner
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,509.37M
- Employees
- 27
- P/E (TTM)
- -15.22
- P/B (TTM)
- 3.92
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.67 | $-0.76 | +0.0899 | +11.83% |
|
Dec 2025 (Q4)
|
$-0.45 | $-0.46 | +0.0065 | +1.42% |
|
Sep 2025 (Q3)
|
$-0.61 | $-0.46 | -0.1459 | -31.44% |
Financial Statements
| Nonoperating Income/Loss | $9.45M |
| Operating Expenses | $95.14M |
| Research and Development | $69.69M |
| Other Operating Expenses | $25.14M |
| Income/Loss From Continuing Operations After Tax | -$85.69M |
| Income/Loss From Continuing Operations Before Tax | -$85.68M |
| Income Tax Expense/Benefit | $1.00K |
| Net Income/Loss | -$85.69M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$85.69M |
| Net Income/Loss Available To Common Stockholders, Basic | -$60.51M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$25.18M |
| Preferred Stock Dividends And Other Adjustments | -$25.18M |
| Basic Earnings Per Share | $0.14 |
| Diluted Earnings Per Share | $0.14 |
| Basic Average Shares | 70,036,242 |
| Diluted Average Shares | 70,036,242 |
| Assets | $361.69M |
| Current Assets | $355.30M |
| Cash | $324.90M |
| Other Current Assets | $30.40M |
| Noncurrent Assets | $6.39M |
| Fixed Assets | $2.20M |
| Other Non-current Assets | $4.19M |
| Liabilities | $29.35M |
| Current Liabilities | $23.56M |
| Accounts Payable | $3.49M |
| Other Current Liabilities | $20.07M |
| Noncurrent Liabilities | $5.78M |
| Equity | $332.35M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $332.35M |
| Liabilities And Equity | $361.69M |
| Net Cash Flow From Operating Activities | -$82.40M |
| Net Cash Flow From Operating Activities, Continuing | -$82.40M |
| Net Cash Flow From Investing Activities | -$44.82M |
| Net Cash Flow From Investing Activities, Continuing | -$44.82M |
| Net Cash Flow From Financing Activities | $387.63M |
| Net Cash Flow From Financing Activities, Continuing | $387.63M |
| Net Cash Flow | $260.42M |
| Net Cash Flow, Continuing | $260.42M |
| Comprehensive Income/Loss | -$85.54M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$85.50M |
| Other Comprehensive Income/Loss | -$66.49M |